- Home
- HSDT vs PHAT Comparison
HSDT vs PHAT Comparison
Compare HSDT & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSDT
- PHAT
- Stock Information
- Founded
- HSDT N/A
- PHAT 2018
- Country
- HSDT United States
- PHAT United States
- Employees
- HSDT N/A
- PHAT N/A
- Industry
- HSDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- HSDT Health Care
- PHAT Health Care
- Exchange
- HSDT Nasdaq
- PHAT Nasdaq
- Market Cap
- HSDT 707.6M
- PHAT 769.0M
- IPO Year
- HSDT N/A
- PHAT 2019
- Fundamental
- Price
- HSDT $5.94
- PHAT $13.55
- Analyst Decision
- HSDT
- PHAT Strong Buy
- Analyst Count
- HSDT 0
- PHAT 5
- Target Price
- HSDT N/A
- PHAT $17.60
- AVG Volume (30 Days)
- HSDT 1.3M
- PHAT 1.3M
- Earning Date
- HSDT 11-14-2025
- PHAT 10-30-2025
- Dividend Yield
- HSDT N/A
- PHAT N/A
- EPS Growth
- HSDT N/A
- PHAT N/A
- EPS
- HSDT N/A
- PHAT N/A
- Revenue
- HSDT $295,000.00
- PHAT $147,190,000.00
- Revenue This Year
- HSDT N/A
- PHAT $213.65
- Revenue Next Year
- HSDT $75.13
- PHAT $91.41
- P/E Ratio
- HSDT N/A
- PHAT N/A
- Revenue Growth
- HSDT N/A
- PHAT 460.30
- 52 Week Low
- HSDT $5.37
- PHAT $2.21
- 52 Week High
- HSDT $1,200.00
- PHAT $19.50
- Technical
- Relative Strength Index (RSI)
- HSDT 34.31
- PHAT 58.66
- Support Level
- HSDT $6.01
- PHAT $13.02
- Resistance Level
- HSDT $7.20
- PHAT $16.08
- Average True Range (ATR)
- HSDT 1.59
- PHAT 1.05
- MACD
- HSDT -0.53
- PHAT -0.02
- Stochastic Oscillator
- HSDT 1.72
- PHAT 44.88
About HSDT Helius Medical Technologies Inc. (DE)
Solana Co is a publicly listed digital asset treasury established in partnership with Pantera and Summer Capital. The company is dedicated to acquiring Solana (SOL) and aims to maximize SOL per share by strategically leveraging capital market opportunities and on-chain activities. Through this model, Solana Company provides public market investors with efficient and direct exposure to Solana's long-term growth potential.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.